Top

Published in:

01-06-2019 | Sarcoma | Original Article

Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy

Authors: Sebastian Klein, Cornelia Mauch, Svenja Wagener-Ryczek, Maximilian Schoemmel, Reinhard Buettner, Alexander Quaas, Doris Helbig

Published in: Cancer Immunology, Immunotherapy | Issue 6/2019

Abstract

Background

Pleomorphic dermal sarcomas (PDS) are sarcomas of the skin with local recurrences in up to 28% of cases, and distant metastases in up to 20%. Although recent evidence provides a strong rational to explore immunotherapeutics in solid tumors, nothing is known about the immune environment of PDS.

Methods

In the current study, a comprehensive immune-phenotyping of 14 PDS using RNA and protein expression analyses, as well as quantitative assessment of immune cells using an image-analysis tool was performed.

Results

Three out of 14 PDS revealed high levels of CD8-positive tumor-infiltrating T-lymphocytes (TILs), also showing elevated levels of immune-related cytokines such as IL1A, IL2, as well as markers that were very recently linked to enhanced response of immunotherapy in malignant melanoma, including CD27, and CD40L. Using a multivariate analysis, we found a number of differentially expressed genes in the CD8-high group including: CD74, LYZ and HLA-B, while the remaining cases revealed enhanced levels of immune-suppressive cytokines including CXCL14. The “CD8-high” PDS showed strong MHC-I expression and revealed infiltration by PD-L1-, PD-1- and LAG-3-expressing immune cells. Tumor-associated macrophages (TAMs) predominantly consisted of CD68 + , CD163 + , and CD204 + M2 macrophages showing an accentuation at the tumor invasion front.

Conclusions

Together, we provide first explorative evidence about the immune-environment of PDS tumors that may guide future decisions whether individuals presenting with advanced PDS could qualify for immunotherapeutic options.

Available only for authorised users

Tardio JC, Pinedo F, Aramburu JA, Suarez-Massa D, Pampin A, Requena L, Santonja C (2016) Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated. J Cutan Pathol 43:101–112. https://doi.org/10.1111/cup.12603 CrossRefPubMed

Miller K, Goodlad JR, Brenn T (2012) Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol 36:1317–1326. https://doi.org/10.1097/PAS.0b013e31825359e1 CrossRefPubMed

Helbig D, Ihle MA, Putz K, Tantcheva-Poor I, Mauch C, Buttner R, Quaas A (2016) Oncogene and therapeutic target analyses in a typical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget 7(16), 21763–21774. https://doi.org/10.18632/oncotarget.7845 CrossRefPubMedPubMedCentral

Helbig D, Quaas A, Mauch C et al (2017) Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget 8:109457–109467. https://doi.org/10.18632/oncotarget.22691 CrossRefPubMedPubMedCentral

Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. https://doi.org/10.1056/NEJMoa1200694 CrossRefPubMedPubMedCentral

Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor Mutational burden and response rate to PD-1 inhibition. N Engl J Med 377:2500–2501. https://doi.org/10.1056/NEJMc1713444 CrossRefPubMedPubMedCentral

Borradori L, Sutton B, Shayesteh P, Daniels GA (2016) Rescue therapy with anti-programmed cell death protein 1 inhibitors (PD-1) of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in 5 cases. Br J Dermatol 175(6):1382-1386 https://doi.org/10.1111/bjd.14642 CrossRefPubMed

McGranahan N, Furness AJ, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463–1469. https://doi.org/10.1126/science.aaf1490 CrossRefPubMedPubMedCentral

Mo Z, Liu J, Zhang Q et al (2016) Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol Lett 12:944–950. https://doi.org/10.3892/ol.2016.4744 CrossRefPubMedPubMedCentral

10.

Nghiem PT, Bhatia S, Lipson EJ et al (2016) PD-1 Blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med 374:2542–2552. https://doi.org/10.1056/NEJMoa1603702 CrossRefPubMedPubMedCentral

11.

Valkenburg KC, de Groot AE, Pienta KJ (2018) Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol 15:366–381. https://doi.org/10.1038/s41571-018-0007-1 CrossRefPubMedPubMedCentral

12.

Barberis I, Martini M, Iavarone F, Orsi A (2016) Available influenza vaccines: immunization strategies, history and new tools for fighting the disease. J Prev Med Hyg 57:E41–E46PubMedPubMedCentral

13.

Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer JG, Ibrani D, Koelle DM, Nghiem P (2013) Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 19:5351–5360. https://doi.org/10.1158/1078-0432.CCR-13-0035 CrossRefPubMedPubMedCentral

14.

Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21:24–33. https://doi.org/10.1016/j.molmed.2014.10.009 CrossRefPubMed

15.

Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567. https://doi.org/10.1038/nature14011 CrossRefPubMedPubMedCentral

16.

Chapuis AG, Ragnarsson GB, Nguyen HN et al. (2013) Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 5: 174ra27. https://doi.org/10.1126/scitranslmed.3004916 CrossRefPubMedPubMedCentral

17.

Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V (2013) MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst 105:1172–1187. https://doi.org/10.1093/jnci/djt184 CrossRefPubMed

18.

Adams JL, Smothers J, Srinivasan R, Hoos A (2015) Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 14:603–622. https://doi.org/10.1038/nrd4596 CrossRefPubMed

19.

Tran E, Robbins PF, Lu YC et al (2016) T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375:2255–2262. https://doi.org/10.1056/NEJMoa1609279 CrossRefPubMedPubMedCentral

20.

McCalmont TH (2012) Correction and clarification regarding AFX and pleomorphic dermal sarcoma. J Cutan Pathol 39:8. https://doi.org/10.1111/j.1600-0560.2011.01851.x CrossRefPubMed

21.

Bankhead P, Loughrey MB, Fernandez JA et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. https://doi.org/10.1038/s41598-017-17204-5 CrossRefPubMedPubMedCentral

22.

Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed

23.

Johnson DB, Estrada MV, Salgado R et al (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 7:10582. https://doi.org/10.1038/ncomms10582 CrossRefPubMedPubMedCentral

24.

Scheel AH, Dietel M, Heukamp LC et al (2016) Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29:1165–1172. https://doi.org/10.1038/modpathol.2016.117 CrossRefPubMed

25.

Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7 CrossRefPubMed

26.

Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837–1846. https://doi.org/10.1016/S0140-6736(16)00587-0 CrossRefPubMed

27.

Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T (2009) Macrophage markers in serum and tumor have prognostic impact in American joint committee on cancer stage I/II melanoma. J Clin Oncol 27:3330–3337. https://doi.org/10.1200/JCO.2008.19.9919 CrossRefPubMed

28.

Auslander N, Zhang G, Lee JS et al (2018) Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med 24:1545–1549. https://doi.org/10.1038/s41591-018-0157-9 CrossRefPubMedPubMedCentral

29.

Chowell D, Krishna S, Becker PD et al (2015) TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc Natl Acad Sci USA 112:E1754–E1762. https://doi.org/10.1073/pnas.1500973112 CrossRefPubMedPubMedCentral

30.

Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128. https://doi.org/10.1126/science.aaa1348 CrossRefPubMedPubMedCentral

31.

Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 371:2189–2199. https://doi.org/10.1056/NEJMoa1406498 CrossRefPubMedPubMedCentral

32.

Van Allen EM, Miao D, Schilling B et al (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:207–211. https://doi.org/10.1126/science.aad0095 CrossRefPubMedPubMedCentral

33.

Qian J, Luo F, Yang J et al (2018) TLR2 Promotes glioma immune evasion by downregulating MHC class II molecules in microglia. Cancer Immunol Res 6:1220–1233. https://doi.org/10.1158/2326-6066.CIR-18-0020 CrossRefPubMed

34.

Starnes T, Rasila KK, Robertson MJ, Brahmi Z, Dahl R, Christopherson K, Hromas R (2006) The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol 34:1101–1105. https://doi.org/10.1016/j.exphem.2006.05.015 CrossRefPubMed

35.

Kudjawu YC, Chatellier G, Decool E, de Maria F, Beltzer N, Gremy I, Meyer G, Eilstein D (2016) Timing in initiating lung cancer treatment after bronchoscopy in France: study from medico-administrative database. Lung Cancer 95:44–50. https://doi.org/10.1016/j.lungcan.2016.02.016 CrossRefPubMed

36.

Mantovani A, Sica A, Locati M (2007) New vistas on macrophage differentiation and activation. Eur J Immunol 37:14–16. https://doi.org/10.1002/eji.200636910 CrossRefPubMed

37.

Falleni M, Savi F, Tosi D, Agape E, Cerri A, Moneghini L, Bulfamante GP (2017) M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma. Melanoma Res 27:200–210. https://doi.org/10.1097/CMR.0000000000000352 CrossRefPubMed

38.

Rodriguez-Ruiz ME, Rodriguez I, Garasa S et al (2016) Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res 76:5994–6005. https://doi.org/10.1158/0008-5472.CAN-16-0549 CrossRefPubMed

39.

Wu Q, Allouch A, Martins I, Modjtahedi N, Deutsch E, Perfettini JL (2017) Macrophage biology plays a central role during ionizing radiation-elicited tumor response. Biomed J 40:200–211. https://doi.org/10.1016/j.bj.2017.06.003 CrossRefPubMedPubMedCentral

40.

Wasiuk A, Testa J, Weidlick J et al (2017) CD27-Mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy. J Immunol 199:4110–4123. https://doi.org/10.4049/jimmunol.1700606 CrossRefPubMedPubMedCentral

41.

Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, Bullock TN (2010) Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 33:769–779. https://doi.org/10.1097/CJI.0b013e3181ee238f CrossRefPubMedPubMedCentral

42.

Soong RS, Song L, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF (2014) Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PLoS One 9:e93162. https://doi.org/10.1371/journal.pone.0093162 CrossRefPubMedPubMedCentral

43.

van Houdt IS, Oudejans JJ, van den Eertwegh AJ et al (2005) Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 11:6400–6407. https://doi.org/10.1158/1078-0432.CCR-05-0306 CrossRefPubMed

44.

Woo SR, Turnis ME, Goldberg MV et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917–927. https://doi.org/10.1158/0008-5472.CAN-11-1620 CrossRefPubMed

45.

Kaufman HL, Russell J, Hamid O et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374–1385. https://doi.org/10.1016/S1470-2045(16)30364-3 CrossRefPubMedPubMedCentral

46.

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627 CrossRefPubMedPubMedCentral

Title: Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy
Authors: Sebastian Klein
Cornelia Mauch
Svenja Wagener-Ryczek
Maximilian Schoemmel
Reinhard Buettner
Alexander Quaas
Doris Helbig
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keyword: Sarcoma
Published in: Cancer Immunology, Immunotherapy / Issue 6/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02339-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2019

Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model

Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas

HCT-116 colorectal cancer cells secrete chemokines which induce chemoattraction and intracellular calcium mobilization in NK92 cells

DNA lesions correlate with lymphocyte function after selective internal radiotherapy

Correction to: Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial

Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer